Greenwich LifeSciences, (id:5532 GLSI)
13.55 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:07:30 AM)
Exchange closed, opens in 1 day 23 hours
4.55 USD (4.55%)
5.04 USD (5.04%)
-2.69 USD (-2.69%)
-2.66 USD (-2.66%)
12.92 USD (12.92%)
135.65 USD (135.65%)
About Greenwich LifeSciences,
Market Capitalization 165.10M
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
| Headquarters (address) |
Building 14 Stafford 77477 TX United States |
| Phone | 832 819 3232 |
| Website | https://greenwichlifesciences.com |
| Employees | 3 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | GLSI |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 8.00 - 21.44 |
| Market Capitalization | 165.10M |
| P/E trailing | -19.64 |
| P/E forward | -15.32 |
| Price/Book | 24.06 |
| Beta | 3.32 |
| EPS | -0.790 |
| EPS United States (ID:6, base:3400) | 24.26 |